Merck Research Laboratories, West Point, Pa. The Evaluation of Losartan in the Elderly (ELITE) study demonstrates how an unexpected finding generates research. ELITE started out as a safety and ...

President Donald Trump’s proposed tariffs, while on hold for now, could have sweeping impacts in Pennsylvania and lead to higher prices on goods ranging from appliances to cars to tomatoes. Following ...

Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...

Mr. Kennedy has referred clients to the firm in cases claiming injuries from the Gardasil vaccine, a Merck product that is meant to prevent cervical cancer that can be caused by the human ...

Merck is investigating WELIREG in rare oncologic diseases, RCC and other tumor types through a broad clinical development program, including in Phase 2 and 3 trials evaluating WELIREG as monotherapy ...

The FDA has granted Priority Review to Merck's supplemental new drug application (sNDA) for Welireg (belzutifan), an oral HIF-2α inhibitor, for treating adult and pediatric patients over 12 years of ...

He says, if confirmed, he can still earn referral fees from a firm suing Merck. In 2020 ... it's not clear whether the issue will be a sticking point for Republicans eager to align with Trump.

Kennedy Jr.'s secretary of the Department of Health and Human Services (HHS) confirmation hearing and how pharma stocks like Pfizer (PFE) and Merck (MRK) may be impacted: "There's been a lot of ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

The Dow Jones Industrial Average is declining Wednesday morning with shares of Merck and Johnson & Johnson seeing the biggest losses for the price-weighted average. Supported by world-class ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target to $119.00. Discover outperforming stocks and invest ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...